Search Results

There are 4204 results for: content related to: Reply

  1. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

    International Journal of Cancer

    Volume 137, Issue 6, 15 September 2015, Pages: 1446–1456, Qiaoli Zhao, Nadine Kretschmer, Rudolf Bauer and Thomas Efferth

    Version of Record online : 6 MAR 2015, DOI: 10.1002/ijc.29483

  2. You have full text access to this Open Access content
    JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

    Cancer Science

    Volume 103, Issue 10, October 2012, Pages: 1795–1802, Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Ohashi, Saburo Takata, Mitsune Tanimoto and Katsuyuki Kiura

    Version of Record online : 23 JUL 2012, DOI: 10.1111/j.1349-7006.2012.02363.x

  3. You have full text access to this Open Access content
    Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib

    Cancer Science

    Volume 100, Issue 9, September 2009, Pages: 1701–1707, Kohji Noguchi, Haruka Kawahara, Airi Kaji, Kazuhiro Katayama, Junko Mitsuhashi and Yoshikazu Sugimoto

    Version of Record online : 12 MAY 2009, DOI: 10.1111/j.1349-7006.2009.01213.x

  4. You have full text access to this Open Access content
    Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case–control study

    Thoracic Cancer

    Volume 3, Issue 1, February 2012, Pages: 27–33, Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou and You Lu

    Version of Record online : 5 FEB 2012, DOI: 10.1111/j.1759-7714.2011.00087.x

  5. Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells

    British Journal of Pharmacology

    Volume 172, Issue 18, September 2015, Pages: 4560–4574, I Kretschmer, T Freudenberger, S Twarock and J W Fischer

    Version of Record online : 30 JUL 2015, DOI: 10.1111/bph.13240

  6. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 6, June 2013, Pages: 809–818, Fabienne Thomas, Paul Delmar, Sébastien Vergez, Philippe Rochaix, Isabelle Hennebelle, Patricia McLoughlin, Adil Benlyazid, Jérôme Sarini and Jean–Pierre Delord

    Version of Record online : 13 JUL 2012, DOI: 10.1002/hed.23036

  7. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 2, April 2015, Pages: 232–239, Y. Emoto-Yamamoto, S. Iida, T. Kawanishi and M. Fukuoka

    Version of Record online : 17 NOV 2014, DOI: 10.1111/jcpt.12232

  8. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

    PROTEOMICS

    Volume 15, Issue 2-3, January 2015, Pages: 340–355, Xu Zhang, Natalya Belkina, Harrys Kishore Charles Jacob, Tapan Maity, Romi Biswas, Abhilash Venugopalan, Patrick G. Shaw, Min-Sik Kim, Raghothama Chaerkady, Akhilesh Pandey and Udayan Guha

    Version of Record online : 15 JAN 2015, DOI: 10.1002/pmic.201400315

  9. EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review

    Lung Cancer, Fourth Edition

    Kathryn F. Mileham, Edward S. Kim, William N. William, Pages: 406–420, 2014

    Published Online : 4 APR 2014, DOI: 10.1002/9781118468791.ch26

  10. ERLOTINIB ACTIVATES MITOCHONDRIAL DEATH PATHWAYS RELATED TO THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN THE HUMAN NON-SMALL CELL LUNG CANCER CELL LINE A549

    Clinical and Experimental Pharmacology and Physiology

    Volume 36, Issue 5-6, May/June 2009, Pages: 487–494, Xia Qian, Jing Li, Jianhua Ding, Zhiyuan Wang, Wenjing Zhang and Gang Hu

    Version of Record online : 8 OCT 2008, DOI: 10.1111/j.1440-1681.2008.05091.x

  11. You have free access to this content
    Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

    Hepatology

    Volume 59, Issue 4, April 2014, Pages: 1577–1590, Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub and Kenneth K. Tanabe

    Version of Record online : 28 FEB 2014, DOI: 10.1002/hep.26898

  12. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 9, September 2013, Pages: 1323–1330, Christina I. Tsien, Mukesh K. Nyati, Aarif Ahsan, Susmita G. Ramanand, Douglas B. Chepeha, Francis P. Worden, Joseph I. Helman, Nisha D'Silva, Carol R. Bradford, Gregory T. Wolf, Theodore S. Lawrence and Avraham Eisbruch

    Version of Record online : 21 AUG 2012, DOI: 10.1002/hed.23128

  13. Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells

    Phytotherapy Research

    Volume 28, Issue 5, May 2014, Pages: 728–735, Yoshikane Yamauchi, Yotaro Izumi, Jun Yamamoto and Hiroaki Nomori

    Version of Record online : 13 AUG 2013, DOI: 10.1002/ptr.5056

  14. You have full text access to this Open Access content
    Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

    Journal of Cellular and Molecular Medicine

    Volume 14, Issue 1-2, January-February 2010, Pages: 51–69, Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell and Barbara Klughammer

    Version of Record online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00991.x

  15. Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 282–290, Dr Paul Frohna, Dr Jianfeng Lu, Dr Steve Eppler, Dr Marta Hamilton, Ms Julie Wolf, Dr Ashok Rakhit, Dr Jie Ling, Dr Saraswati R. Kenkare-Mitra and Dr Bert L. Lum

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005284193

  16. You have free access to this content
    Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

    Cancer

    Volume 118, Issue 23, 1 December 2012, Pages: 5903–5911, Jonathan W. Goldman, Isett Laux, Feng Chai, Ronald E. Savage, Dora Ferrari, Edward G. Garmey, Richard G. Just and Lee S. Rosen

    Version of Record online : 17 MAY 2012, DOI: 10.1002/cncr.27575

  17. Concurrent inhibition of NF-κB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer

    Journal of Cellular Biochemistry

    Volume 110, Issue 1, 1 May 2010, Pages: 171–181, Shadan Ali, Sanjeev Banerjee, Jacqueline M. Schaffert, Bassel F. El-Rayes, Philip A. Philip and Fazlul H. Sarkar

    Version of Record online : 8 MAR 2010, DOI: 10.1002/jcb.22523

  18. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC

    Asia-Pacific Journal of Clinical Oncology

    Volume 11, Issue 1, March 2015, Pages: 4–14, Michael Michael, Shane C White, Ehtesham Abdi, Louise Nott, Phillip Clingan, Allan Zimet, Peter Button, Daniel Gregory, Benjamin Solomon, Alexander Dobrovic, Hongdo Do and Stephen Clarke

    Version of Record online : 27 FEB 2014, DOI: 10.1111/ajco.12178

  19. You have free access to this content
    Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models

    International Journal of Cancer

    Volume 130, Issue 10, 15 May 2012, Pages: 2445–2454, Mi Young Cha, Kwang-Ok Lee, Mira Kim, Ji Yeon Song, Kyu Hang Lee, Jongmin Park, Yun Jung Chae, Young Hoon Kim, Kwee Hyun Suh, Gwan Sun Lee, Seung Bum Park and Maeng Sup Kim

    Version of Record online : 24 AUG 2011, DOI: 10.1002/ijc.26276

  20. Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 12, December 2014, Pages: 3810–3833, Jie Shao, John S. Markowitz, Di Bei and Guohua An

    Version of Record online : 10 OCT 2014, DOI: 10.1002/jps.24113